

Cigna HS Custom EQUIPP Cigna HS Custom Measure - Statin Initiation in Patients with Diabetes

Displayed as: Statin Initiation in Patients with Diabetes

Description

- A custom activity-based rating from Cigna Healthspring which will be incentivized to the eligible pharmacy
- This custom measure designed by Cigna Healthspring identifies and measures the percentage of the Statin Use in Persons with Diabetes (SUPD) measure qualifying population that has never filled a statin medication
- This measure rates the percentage of statin naive patients with a diagnosis of diabetes between 40 and 75 years of age who have newly received a statin medication
- Using pharmacy claims data, the eligible patient population must meet the following criteria:
 - o Having 2 or more fills of a diabetes medication within the measurement period
 - o Must not have record of a statin fill occuring up to one year prior to the first fill of diabetes medications in the measurement period.
 - o An eligibility run-in period of 120 days determines newly eligible plan members are statin naive to be included in the qualifying measure population
- The pharmacy which fills the majority of the member's diabetic medications will receive the qualifying member attribution.
- The first pharmacy to fill a statin for the qualified member will receive credit for the gap closure (or numerator status)

Did You Know?*

- Patients with diabetes who take statin medications lower their risk of developing heart disease
- Risks for heart disease include:
 - o High cholesterol
 - o High blood pressure
- o High level of sodium in a
- o Being overweight or obese

o Smoking

person's diet

o Low level of physical activity

Calculation

NUMERATOR =

Patients from the denominator who have received a fill of at least one statin medication after the second fill of an eligible diabetes medication

DENOMINATOR =

Statin naive patients who have had two or more fills of a diabetes medication

Example

With this measure, if the population performance score for the SUPD measure was 70%, this statin initiation measure is evaluating which patients from the remaining 30% newly receive a statin medication.

Exclusions

Patients with a diagnosis of End Stage Renal Disease

*Healthline Newsletter -

https://www.healthline.com/health/ statins-for-diabeticswhich-is-best

Pharmacy Times -

https://www.pharmacytimes.com/ contributor/david-kim/2017/12/statintherapy-in-patients-with-diabetes



PHARMACY QUALITY SOLUTIONS